Browse studies

Find your next paid study

8 recruiting studies matching your filters

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL OLE

This is a Phase 2, multicenter, open-label, extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR 1-3-sel…

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

QED Therapeutics, a BridgeBio companyNCT05145010

Phase 2

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participant…

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

BioMarin PharmaceuticalNCT07441876

VIrtual STudy in Achondroplasia for the US (VISTA)

This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated …

Achondroplasia

Estimated

~$10 – $1,050

Actual pay is set by the research site.

BioMarin PharmaceuticalNCT06168201

Registry of Patients With Bone Disorders

The purpose of this study is to create an electronic registry to house phenotypic information from patients with achondroplasia. The initial focus of this regi…

Achondroplasia

Estimated

~$10 – $750

Actual pay is set by the research site.

Johns Hopkins UniversityNCT02597881

Phase 2

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period

This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety,…

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Ascendis Pharma A/SNCT06079398

Phase 2

Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia

This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants \< 3 years old with AC…

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

QED Therapeutics, a BridgeBio companyNCT07169279

Phase 2

A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates: BEACH301

The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with …

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Tyra Biosciences, IncNCT06842355

Phase 2

A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia

TransCon CNP administered once-weekly in children and adolescents with achondroplasia who have completed a prior TransCon CNP clinical trial. Participants who …

Achondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Ascendis Pharma Growth Disorders A/SNCT05929807